Article info
PDFLetter
Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development
- Correspondence to Dr Vivianne Malmström, Department of Medicine (Solna), Karolinska Universitetssjukhuset i Solna, Stockholm, 171 64, Sweden; vivianne.malmstrom{at}ki.se; Dr Bruno Raposo, Department of Medicine (Solna), Karolinska Universitetssjukhuset i Solna, Stockholm, 171 64, Sweden; bruno.raposo{at}ki.se
Citation
Divergent and dominant anti-inflammatory effects of patient-derived anticitrullinated protein antibodies (ACPA) in arthritis development
Publication history
- Received September 30, 2022
- Accepted December 28, 2022
- First published January 5, 2023.
Online issue publication
October 18, 2023
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.